Poly Medicure · Material risks, their source context, and severity in the latest available quarter.
ConCallIQ research layer
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Chinese companies using FDA 510(k) route to import products at zero duty into India, severely impacting domestic renal business. Company has raised this concern with government officials. Dialysis machine sales tracking 450 vs. initial 500-600 guidance.
International organic business excluding acquisitions is currently flattish due to European market weakness, MDR transition delays, and NHS contract deferrals. China dumping also affecting export markets globally.
Company strategically reducing government business exposure (from 10-12% to 6-7%) due to lower prices and payment delays, though this impacts overall growth trajectory and market reach.
Newly acquired Pentrocare and CTF Group currently operating at 50-60% capacity utilization with lower EBITDA margins, causing consolidated margins to be lower than standalone. Full impact will be visible in FY27.
